Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.

NCT00692770 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00692770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00692770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
August 15, 2008
Completion date
November 28, 2014
Enrollment
1,114 (actual)
Sites
199

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular